Clinical Trials Logo

Stroke clinical trials

View clinical trials related to Stroke.

Filter by:
  • Not yet recruiting  
  • Page 1 ·  Next »

NCT ID: NCT03392792 Not yet recruiting - Clinical trials for All Patients With Ischemic Cerebrovascular Stroke Aged =18 Years of Both Sex

Regisry of the Stroke Patients in Assiut University Hospital

Start date: December 30, 2018
Phase: N/A
Study type: Interventional

• Aim of the work To register all type of acute stroke admitted in Assiut university Hospital and assessment of their risk factor, morbidity and Mortality

NCT ID: NCT03391713 Not yet recruiting - Stroke, Acute Clinical Trials

The Effectiveness of Waiting Room Posters for Stroke Education

Start date: January 2018
Phase: N/A
Study type: Interventional

The purpose of this study is to determine the effectiveness of posters in improving patient awareness and knowledge of the signs and symptoms of stroke. The control group study will be conducted in the first two weeks. Subsequently, the intervention arm will occur in the subsequent two weeks.

NCT ID: NCT03389529 Not yet recruiting - Clinical trials for Coronary Artery Disease

the Change of Cholesterol Efflux Capacity and Coronary Artery Disease in Real Clinical Practice

Start date: March 1, 2018
Phase: N/A
Study type: Observational

The purpose of this study is to investigate the change of cholesterol efflux capacity in patients with coronary artery disease treated with secondary prevention drugs, and the correlation with the prognosis.

NCT ID: NCT03385928 Not yet recruiting - Clinical trials for Intracerebral Haemorrhage

STOP-AUST Ambulance: Stopping Haemorrhage With Tranexamic Acid cOmmenced Prehospital - AUSTralia in a Mobile Stroke Ambulance.

Start date: January 12, 2018
Phase: Phase 2
Study type: Interventional

The study will be prospective phase II randomised, double-blind, placebo-controlled, investigator-driven trial in acute intracerebral haemorrhage patients. The study has 2 arms with 1:1 randomisation to either intravenous Tranexamic acid or placebo and will test the hypothesis that ICH (intracranial haemorrhage) patients treated with intravenous tranexamic acid within 2 hours of symptom onset will have lower rates of haematoma growth than compared to placebo.

NCT ID: NCT03380481 Not yet recruiting - Stroke Clinical Trials

SouthErn China REgisTry for Stroke on Traditional Chinese Medicine

Start date: December 25, 2017
Phase: N/A
Study type: Observational [Patient Registry]

Stroke is the first most common cause of death in China and one of the major causes of functional disability in the adult population.The burden of stoke is significantly increased in China in recent years. In order to investigate the prognosis of stroke, with diagnostic and treatment information of traditional Chinese medicine (TCM), and assess the effectiveness and safety of TCM for stroke in southern China, the investigators will conduct this multicenter prospective registry study in southern China. This study will recruit 10,000 consecutive eligible patients with acute stroke from more than 50 hospitals. 24 months follow-up will be carried out on-site in hospitals and by telephone to track endpoint (including all-cause mortality, composite cerebrovascular and cardiovascular events at one and two year follow up, and neurological and functional assessments).

NCT ID: NCT03379857 Not yet recruiting - Stroke Clinical Trials

Prevalence of Strokes Secondary to a Reversible Cerebral Vasoconstriction Attributable to Cannabis Consumption in Young Subjects (≤ 45 Years) Hospitalized for an Ischaemic Stroke

Start date: January 2018
Phase: N/A
Study type: Interventional

Incidence of strokes has increased these last 20 years in young population. This rise could be linked to alcohol, tobacco or drug use like cannabis. Cannabis has previously been descripted as a potential factor of reversible vasoconstriction. The main objective is to show that an exhaustive assessment of a stroke facing a young person frequently lead to a diagnostic of reversible vasoconstriction due to cannabis use. Evaluation will focus on prevalence of strokes secondary to a reversible vasoconstriction attributable to cannabis in young subjects. There's a real public healthcare interest in terms of primary and secondary prevention to evaluate the role of cannabis as a risk factor of stroke in young population.

NCT ID: NCT03379532 Not yet recruiting - Stroke Clinical Trials

BCI-controlled NMES in Subacute Stroke

Start date: February 2018
Phase: N/A
Study type: Interventional

Stroke patients with severe upper limb movement deficits have limited treatment options and often remain severely handicapped at the chronic stage. Recent findings have suggested that poor motor recovery can be due to severe damage of the cortico-spinal tract (CST), the neural fibres connecting the movement regions of the brain to the spinal cord. Hence, to improve recovery of upper limb movements it will be crucial to re-establish and strengthen CST projections. Recent studies provided evidence that closed-loop brain computer interface-driven electrical stimulation of the paretic muscles can induce clinically important and lasting recovery of upper limb function, even in patients with chronic, severe motor affection. In this treatment approach, movement intentions of the patients are detected with electroencephalography and real-time analyses. This triggers an electrical stimulation of affected upper limb muscles. In this study, the investigators hypothesize that neuromuscular electrical stimulation (NMES) applied contingent to voluntary activation of primary motor cortex, as detected by a brain-computer interface (BCI), can help restore CST projections. This might improve recovery of patients with severe upper limb movement deficits. Treatment will be started within the first 8 weeks after stroke onset.

NCT ID: NCT03375762 Not yet recruiting - Ischemic Stroke Clinical Trials

REMOTE Ischemic Perconditioning Among Acute Ischemic Stroke Patients ( REMOTE-CAT)

Start date: June 1, 2018
Phase: N/A
Study type: Interventional

Stroke is one of the leading causes of death worldwide and the main cause of incapacity. Currently, the only therapies for acute ischemic stroke (AIS) patients are the administration of recombinant tissue plasminogen activator (rt-PA) and/or endovascular treatment. Unfortunately, many patients cannot benefit from these therapies due to contraindications or evolution time. Neuroprotective therapies could not only increase the benefits of available reperfusion therapies but also provide an option for patients who are not candidates for these treatments. Remote ischemic conditioning, consisting on brief episodes of transient limb ischemia, represents a new paradigm in neuroprotection. It can be categorized in pre-, per- or postconditioning, depending on the moment of application. According to studies in coronary ischemia, remote ischemic perconditioning (RIPerC) during the ischemic event is safe, cost-effective, feasible and associated with a reduction in myocardial injury. The investigators aim to conduct a multicentre study (5 university hospitals) of pre-hospital RIPerC in AIS patients (within 8 hours of stroke onset), which would include 572 stroke code activated patients (286 would undergo RIPerC and 286 would be sham). Our hypothesis is that RIPerC would be safe and would induce endogenous neuroprotective phenomena associated with good outcomes in AIS patients whether treated with revascularization therapies or not. Moreover, the development of systemic ischemic tolerance should provide metabolomic and lipidomic signatures that would present an opportunity to find specific molecular markers (biomarkers). The main objectives will be to assess: 1) RIPerC clinical benefits in AIS, 2) whether RIPerC is safe not only in AIS but also in all cases of stroke code activation, 3) whether RIPerC is associated with a reduction in cerebral infarct size and 4) metabolomic and lipidomic signatures of the RIPerC effect.

NCT ID: NCT03367091 Not yet recruiting - Stroke Clinical Trials

Energy Consumption and Cardiorespiratory Load During Overground Gait Training With a Wearable Exoskeleton After Stroke

Start date: February 2018
Phase: N/A
Study type: Interventional

To investigate acute metabolic and cardiorespiratory responses during overground gait training with a wearable exoskeleton in persons after stroke

NCT ID: NCT03364296 Not yet recruiting - Stroke, Acute Clinical Trials

Biological Dating of Cerebral Ischemia With GST-π/PRDX1 to Detect Patients With Stroke of Unknown Onset Within the Therapeutic Window of Thrombolysis

Start date: January 1, 2018
Phase: N/A
Study type: Interventional

The FLAG1 study will assess the diagnostic performance of biomarkers Glutathion S-Transferase-π (GST-π) and Peroxyredoxin 1 (PRDX1) to identify cerebral infarction of less than 4,5 hours in a population of patients with neurological deficiency of less than 12 hours.